Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 201–300 of 892
Recent Advances in Antifungal Prevention and Treatment
Groll, A. H., & Tragiannidis, A. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.03.003 · Cited by 51
Candida glabrata – unique features and challenges in the clinical management of invasive infections
Glöckner, A., & Cornely, O. A. (2015) · Mycoses · doi:10.1111/myc.12348 · Cited by 49
Paradoxical echinocandin activity: a limited in vitro phenomenon?
Wiederhold, N. P. (2009) · Medical Mycology · doi:10.1080/13693780802428542 · Cited by 48
Chiotos, K., Vendetti, N., Zaoutis, T. E., Baddley, J., Ostrosky-Zeichner, L., Pappas, P., & Fisher, B. T. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw305 · Cited by 48
Self-citationDeJarnette, C. A., Luna-Tapia, A., Estredge, L. R., & Palmer, G. E. (2020) · mSphere · doi:10.1128/msphere.00374-20 · Cited by 54
Fungal infections in lung transplant recipients
Silveira, F. P., & Husain, S. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3282f9b1d1 · Cited by 47
Glöckner, A. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-167 · Cited by 52
Ko, J., Jung, D. S., Lee, J. Y., Kim, H. A., Ryu, S. Y., Jung, S., Joo, E., Cheon, S., Ys, K., Kim, S., et al. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.05.017 · Cited by 46
Synthesis and biological evaluation of new eugenol mannich bases as promising antifungal agents
Abrão, P. H. O., Pizi, R. B., de Souza, T. B., Silva, N. C., Fregnan, A. M., Silva, F. N., Coelho, L. F. L., Malaquias, L. C. C., Dias, A. L. T., Dias, D. F., et al. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12504 · Cited by 45
Susceptibility Test Methods: Yeasts and Filamentous Fungi
Johnson, E. M., & Arendrup, M. C. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch131 · Cited by 46
Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 45
Cortés, J. A., Ruiz, J. F., Moreno, L. N. M., & Lemos, E. V. (2020) · Biomédica · doi:10.7705/biomedica.4400 · Cited by 61
“Sin embargo, en los estudios clínicos no se ha determinado una diferencia estadísticamente significativa a favor de ninguno de los productos (51).”
BackgroundJensen, J. S., Hein, L., Lundgren, B., Bestle, M. H., Mohr, T. T., Andersen, M. H., Løken, J., Tousi, H., Søe‐Jensen, P., Lauritsen, A. Ø., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000746 · Cited by 50
Pre-Existing Liver Disease and Toxicity of Antifungals
Spernovasilis, N. A., & Kofteridis, D. P. (2018) · Journal of Fungi · doi:10.3390/jof4040133 · Cited by 48
“Anidulafungin AEs, including DILI, are generally infrequent [159,160].”
BackgroundAntifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis
Mills, E. J., Perri, D., Cooper, C., Nachega, J. B., Wu, P., Tleyjeh, I. M., & Phillips, P. (2009) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-8-23 · Cited by 45
“001) in favor of anidulafungin[22]; and micafungin to caspofungin (RR 1.”
EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole
Cavling Arendrup, M., Cuenca‐Estrella, M., Lass‐Flörl, C., Hope, W. W., & The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST‐AFST) (2014) · Mycoses · doi:10.1111/myc.12170 · Cited by 43
Tascini, C., Sozio, E., Corte, L., Sbrana, F., Scarparo, C., Ripoli, A., Bertolino, G., Merelli, M., Tagliaferri, E., Corcione, A., et al. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1384956 · Cited by 47
“Moreover, fluconazole it has proved less effective in patients with high APACHE score [30], as confirmed by our study.”
ResultJørgensen, K. M., Astvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00073-19 · Cited by 42
“The isolates derived from the entire country and the following clinical specimens: blood as part of the national surveillance program (915 specimens), airways/lung/pleura/sinus (404), other normally sterile sites (47), urine (20), skin/scalp/nail (24), cervix/vagina/urethra (13), other superficial sites (39), and othe…”
BackgroundZilberberg, M. D., & Shorr, A. F. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.008 · Cited by 42
“Anidulafungin, however, did not lead to higher survival rates.(83) This report has been criticized, because one site in the study enrolled a disproportionate number of subjects.”
Leroux, S., & Ullmann, A. J. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12426 · Cited by 47
“anidulafungin [12,15].”
Candidemia in the critically ill patient
Picazo, J. J., González‐Romo, F., & Candel, F. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70005-0 · Cited by 50
“[14] Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D,”
BackgroundPlayford, E. G., Eggimann, P., & Calandra, T. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283177967 · Cited by 46
Prevention and treatment of invasive fungal diseases in neutropenic patients
Almyroudis, N. G., & Segal, B. H. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832e074d · Cited by 46
Early Clinical Experience with Anidulafungin at a Large Tertiary Care Medical Center
Brielmaier, B. D., Casabar, E., Kurtzeborn, C. M., McKinnon, P. S., & Ritchie, D. J. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.1.64 · Cited by 42
Echinocandins — First-Choice or First-Line Therapy for Invasive Candidiasis?
Sobel, J. D., & Revankar, S. G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078078 · Cited by 42
Update on therapeutic approaches for invasive fungal infections in adults
Boutin, C.-A., & Luong, M. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231224980 · Cited by 54
Intra-abdominal Sepsis: Newer Interventional and Antimicrobial Therapies
Solomkin, J. S., & Mazuski, J. E. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.007 · Cited by 50
An Italian consensus for invasive candidiasis management (ITALIC)
Scudeller, L., Viscoli, C., Menichetti, F., Bono, V. D., Cristini, F., Tascini, C., Bassetti, M., & Viale, P. (2013) · Infection · doi:10.1007/s15010-013-0558-0 · Cited by 49
“Recently, a systematic review of all randomised antifungal clinical trials in documented candidaemia and deep-seated Candida disease which led to the approval of the three available echinocandins showed that the administration of an echinocandin, as compared with any other antifungal therapy, was significantly associa…”
BackgroundEchinocandin Resistance in Candida Species: a Review of Recent Developments
Wiederhold, N. P. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0549-2 · Cited by 48
Kumar, A., Zarychanski, R., Pisipati, A., Kumar, A., Kethireddy, S., & Bow, E. J. (2018) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2017.1421592 · Cited by 47
“…,m ax :m ax im um ,I V: in tr av en ou s. and symptoms of infection along with initial microbiological clearance from blood and/or tissues in seven of eight cases (Rex et al. 1994, 2003; AbeleHorn et al. 1996; Anaissie et al. 1996; Phillips et al. 1997; Kullberg et al. 2005; Reboli et al. 2007).”
BackgroundMethodResultInfluentialPatient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy
Davidson, L., Netea, M. G., & Kullberg, B. J. (2018) · Journal of Fungi · doi:10.3390/jof4010009 · Cited by 50
“Remarkably, neutropenia is only present in less than 5% of patients with candidemia [108,109].”
BackgroundRecommendations for the management of candidemia in adults in Latin America
Nucci, M., Thompson-Moya, L., Guzman-Blanco, M., Tiraboschi, I. N., Cortes, J. A., Echevarría, J., Sifuentes, J., Zurita, J., Santolaya, M. E., Alvarado Matute, T., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.007 · Cited by 41
Zaragoza, R., Perman, J., Salavert, M., Viudes, Solé, A., Jarque, I., Cantón, R., Monte‐Boquet, E., & Romá, E. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3994 · Cited by 46
“Finally, anidulafungin is the only antifungal compound that has been able to demonstrate superiority over fl uconazole in IC (Reboli et al 2007), although we must be cautious with the results presented as the study involved was powered a priori for equivalency.”
López-Cortés, L. E., Almirante, B., Cuenca‐Estrella, M., Garnacho‐Montero, J., Padilla, B., Puig‐Asensio, M., Ruíz-Camps, I., Rodríguez‐Baño, J., Padilla, B., Muñóz, P., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.05.008 · Cited by 44
Warn, P. A., Livermore, J., Howard, S., Felton, T. W., Sharp, A., Gregson, L., Goodwin, J., Petraitiene, R., Petraitis, V., Cohen-Wolkowiez, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05826-11 · Cited by 41
“Anidulafungin is an effective compound for the treatment of invasive candidiasis in adults (17).”
BackgroundSelf-citationOliva, A., Rosa, F. G. D., Mikulska, M., Pea, F., Sanguinetti, M., Tascini, C., & Venditti, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2240956 · Cited by 51
“This recommendation is mainly based on trials comparing caspofungin or micafungin versus AmB (deoxycholate or liposomal, respectively), showing similar effectiveness but fewer adverse events [96,97], or a randomized controlled trial showing non-inferiority of anidulafungin versus fluconazole [98].”
MethodWilke, M. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-180 · Cited by 38
The epidemiology of non‐Candida yeast isolated from blood: The Asia Surveillance Study
Lin, S., Lu, P., Tan, B. H., Chakrabarti, A., Wu, U., Yang, J.-H., Patel, A. K., Li, R. Y., Watcharananan, S. P., Liu, Z., et al. (2018) · Mycoses · doi:10.1111/myc.12852 · Cited by 45
Roilides, E., Carlesse, F. A. D. M. C., Leister-Tebbe, H. K., Conte, U., Yan, J. L., Liu, P., Tawadrous, M., Aram, J. A., & Queiroz‐Telles, F. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002237 · Cited by 39
Nguyen, K. T., Ta, P., Hoang, B. T., Cheng, S., Hao, B., Nguyen, M. H., & Clancy, C. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01480-08 · Cited by 38
“Regardless of the mechanism, the clinical significance of elevated anidulafungin MICs remains unclear (22).”
BackgroundPharmacology and Antifungal Properties of Anidulafungin, a New Echinocandin
Estes, K. E., Penzak, S. R., Calis, K. A., & Walsh, T. J. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.1.17 · Cited by 38
“Most recently, a randomized, double-blinded, noninferiority trial was conducted to compare anidulafungin with fluconazole for the treatment of invasive candidiasis.(59) The study included 245 patients aged 16 years or older with candidemia (at least one positive blood culture) or other types of invasive candidiasis (a…”
MethodSelf-citationInvasive candidiasis and candidemia: from current opinions to future perspectives
Rüping, M., Vehreschild, J. J., & Cornely, O. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902911440 · Cited by 46
“Critics may argue that based on subgroup analyses of the clinical trials by Reboli [96] et al.”
BackgroundMethodInfluentialBienvenu, A., Pradat, P., Guérin, C., Aubrun, F., Fellahi, J.-L., Friggeri, A., Guichon, C., Hernu, R., Ménotti, J., Monard, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.037 · Cited by 40
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective
Ordaya, E. E., Clement, J., & Vergidis, P. I. (2023) · Mycopathologia · doi:10.1007/s11046-023-00759-5 · Cited by 45
Kale‐Pradhan, P. B., Morgan, G., Wilhelm, S. M., & Johnson, L. B. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1207 · Cited by 37
“In contrast to the other four trials that used amphotericin, one trial used fluconazole as the comparator agent.(21) In the C.”
ResultPersistent Candidemia: Causes and Investigations
Nucci, M. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0039-1 · Cited by 37
“[ 19 ] 2007 Prospective, RCT, adults with candidemia 227 Not reported Persistently positive blood cultures at the end of IV treatment 27 of 227 (12%): 7.5% anidulafungin, 17% fluconazole (P=0.03) Not reported”
BackgroundInfluentialEpidemiology, Risk Factors, and Therapy of Candidemia in Pediatric Hematological Patients
Cugno, C., & Cesaro, S. (2012) · Pediatric Reports · doi:10.4081/pr.2012.e9 · Cited by 37
Roilides, E., Carlesse, F. A. D. M. C., Tawadrous, M., Leister-Tebbe, H. K., Conte, U., Raber, S. R., Swanson, R., Yan, J. L., Aram, J. A., Queiroz‐Telles, F., et al. (2020) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002568 · Cited by 37
“6%).(6) Furthermore, results for anidulafungin exposure in this study were comparable to the reported range of steady-state population PK parameters in adults with fungal infections receiving the standard anidulafungin dose (200 mg loading dose followed by 100 mg maintenance dose): steady-state area under the plasma c…”
Alothman, A. F., Al-Musawi, T., Al-Abdely, H. M., Salman, J. A., Almaslamani, M., Yared, N., Butt, A. A., Raghubir, N., Morsi, W. E., & Althaqafi, A. (2013) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2013.08.002 · Cited by 41
Bow, E. J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06906.x · Cited by 39
“Anidulafungin has been shown to be superior to FLU for the treatment of patients with candidaemia (Reboli et al, 2007).”
BackgroundAntifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Liu, P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01473-12 · Cited by 35
“In addition, the effect of weight on efficacy was assessed for ICC patients from the pivotal phase 3 study, where the 200/ 100-mg dosing regimen was evaluated (16).”
BackgroundHow urgent is the need for new antifungals?
Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies
Gumbo, T. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1bea3 · Cited by 35
Antifungal treatment strategies in high risk patients
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01572.x · Cited by 38
Candida Pathogenicity and Interplay with the Immune System
Valand, N., & Girija, U. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-67452-6_11 · Cited by 41
Recommendations for the management of candidemia in children in Latin America
Santolaya, M. E., Telles, F. D. Q., Matute, T. A., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.010 · Cited by 38
Candidemia in the 21st Century
Chang, A., Neofytos, D., & Horn, D. (2008) · Future Microbiology · doi:10.2217/17460913.3.4.463 · Cited by 43
“Similarly, anidulafungin and micafungin have been successfully compared with fluconazole and caspofungin, respectively, in recent prospective trials for the treatment of candidemia [42,43].”
ResultInvasive candidiasis: update on current pharmacotherapy options and future perspectives
Tragiannidis, A., Tsoulas, C., Kerl, K., & Groll, A. H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.805204 · Cited by 40
“Fluconazole, although considered the drug of choice for treatment of IC/candidemia and graded as A-I in some guidelines, has been shown to be inferior to anidulafungin in non-neutropenic patients with candidemia in a post hoc analysis [89].”
ResultHeimann, S. M., Cornely, O. A., Wisplinghoff, H., Kochanek, M., Stippel, D. L., Padosch, S. A., Langebartels, G., Reuter, H., Reiner, M., Vierzig, A., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2230-8 · Cited by 37
Candida spp. bloodstream infection: influence of antifungal treatment on outcome
Ortega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., Pitart, C., & Mensa, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp495 · Cited by 33
Fungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.013 · Cited by 33
Lunel, F. M. V., Donnelly, J. P., van der Lee, H. A. L., Blijlevens, N. M. A., & Verweij, P. E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02654.x · Cited by 38
“Invasive Candida infections continue to be associated with significant morbidity and mortality [1], despite the availability of new potent antifungal agents such as the echinocandins [2,3].”
BackgroundFungal Infections in Cancer Patients
Angarone, M. (2014) · Cancer treatment and research · doi:10.1007/978-3-319-04220-6_4 · Cited by 34
Dudiuk, C., Macedo, D., Leonardelli, F., Theill, L., Cabeza, M. S., Gamarra, S. P., & García‐Effrón, G. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02644-16 · Cited by 37
Doğan, Ö., Yesilkaya, A., Menekşe, Ş., Güler, Ö., Karakoç, Ç., Çınar, G., Kapmaz, M., Aydın, M., Keske, Ş., Şahin, S., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105992 · Cited by 36
“To date, there is only one randomised controlled study comparing fluconazole with an echinocandin for the treatment of Candida BSI, in which fluconazole was associated with lower success rates compared with anidulafungin [20] .”
BackgroundRausch, C. R., DiPippo, A. J., Jiang, Y., Dinardo, C. D., Kadia, T. M., Maiti, A., Bravo, G. M., Ravandi, F., & Kontoyiannis, D. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac230 · Cited by 35
Guinea, J., & Bouza, E. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.603 · Cited by 33
Managing bloodstream infections in patients who have short-term central venous catheters
O’Grady, N. P., & Chertow, D. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.10015 · Cited by 32
Pulmonary Infections Following Lung Transplantation
Witt, C. A., Meyers, B. F., & Hachem, R. R. (2012) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2012.04.006 · Cited by 36
“[49] [50] [51] Amphotericin B is effective for invasive candidiasis; however, given its toxicity and the effectiveness of safer echinocandins and azoles, it should be reserved for treatment failures or patients who are intolerant of echinocandins and are infected by organisms that are resistant to azole agents.”
How to select an antifungal agent in critically ill patients
Dimοpoulos, G., Antonopoulou, A., Armaganidis, A., & Vincent, J. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2013.04.006 · Cited by 35
“In a double-blind, randomized, multicenter, non-inferiority trial comparing anidulafungin versus fluconazole in the treatment of candidemia or invasive candidiasis, Reboli et al [73] showed that anidulafungintreated patients had a higher successful global response rate”
BackgroundWilson, D. T., Drew, R. H., & Perfect, J. R. (2009) · Mycopathologia · doi:10.1007/s11046-009-9193-9 · Cited by 34
“However, when data from the site enrolling the most subjects were removed from the analysis, superiority of anidulafungin was not shown [96].”
BackgroundSafety of micafungin in infants: insights into optimal dosing
Ascher, S. B., Smith, P. B., & Benjamin, D. K. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.545345 · Cited by 34
“Echinocandins may play an increasingly important role in the treatment of invasive Candida infections with the rising incidence of both non-albicans species and fluconazole-resistant Candida species in the NICU [9] and studies demonstrating similar efficacy and improved safety profiles when compared to amphotericin B…”
BackgroundThe End of an Era in Defining the Optimal Treatment of Invasive Candidiasis
Clancy, C. J., & Nguyen, M. H. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis023 · Cited by 31
García‐Effrón, G., Park, S., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01350-10 · Cited by 34
“parapsilosis sensu lato species respond to echinocandin therapy (20, 25, 36).”
BackgroundNeoh, C. F., Liew, D., Slavin, M. A., Marriott, D., Chen, S. C. A., Morrissey, O., Stewart, K., & Kong, D. C. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr186 · Cited by 36
Development of Lipo-γ-AA Peptides as Potent Antifungal Agents
Zhang, X., Wang, M., Zhu, X., Peng, Y., Fu, T., Hu, C., Cai, J., & Liao, G. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00595 · Cited by 34
Cohen‐Wolkowiez, M., Moran, C., Benjamin, D. K., & Smith, P. B. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283321ccc · Cited by 35
Our 2014 approach to candidaemia
Koehler, P. A., Tacke, D., & Cornely, O. A. (2014) · Mycoses · doi:10.1111/myc.12207 · Cited by 33
Hope, W. W., Natarajan, P., & Goodwin, L. C. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-5-507 · Cited by 38
Management of Invasive Candidiasis in the Intensive Care Unit
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Drugs · doi:10.2165/10898550-000000000-00000 · Cited by 30
“Reboli et al.([83]) Neutropenic or non-neutropenic with”
Coping with Candida Infections
Evans, S. E. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200907-075al · Cited by 32
“A head-tohead comparison of anidulafungin to fluconazole for initial therapy of invasive candidiasis demonstrated significantly better success rates for anidulafungin (71).”
BackgroundNeoh, C. F., Slavin, M. A., Chen, S. C. ‐., Stewart, K., & Kong, D. C. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.08.010 · Cited by 32
Invasive Candidiasis: Epidemiology and Risk Factors
Cortés, J. A., & Corrales, I. F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81813 · Cited by 34
Demir, K. K., Butler‐Laporte, G., Corpo, O. D., Ekmekjian, T., Sheppard, D. C., Lee, T. C., & Cheng, M. P. (2021) · Mycoses · doi:10.1111/myc.13290 · Cited by 33
Berg, T., Aehling, N., Bruns, T., Welker, M., Weismüller, T. J., Trebicka, J., Tacke, F., Strnad, P., Sterneck, M. R., Settmacher, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2255-7246 · Cited by 32
Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia
Eschenauer, G. A., Nguyen, M.-H., & Clancy, C. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015590838 · Cited by 29
“In the anidulafungin versus fluconazole study, outcomes were similar between groups for patients with APACHE II scores higher than 20.(16) However, a separate subgroup analysis was performed of this study, which compared treatment groups in patients with “critical illness,” defined as an APACHE II score ≥15, severe se…”
BackgroundMethodResultInfluentialContemporary Strategies in the Prevention and Management of Fungal Infections
Koehler, P. A., & Cornely, O. A. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.003 · Cited by 28
Muñóz, P., Vena, A., Padilla, B., Valerio, M., Sánchez, M. I. T., Puig‐Asensio, M., Fortün, J., Fernández‐Ruiz, M., Merino, P., Losa, J. E., et al. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.02.014 · Cited by 28
Essentials in Candida bloodstream infection
Mellinghoff, S. C., Cornely, O. A., & Jung, N. (2018) · Infection · doi:10.1007/s15010-018-1218-1 · Cited by 32
Bal, A. M., Shankland, G. S., Scott, G., Imtiaz, T., Macaulay, R., & McGill, M. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12231 · Cited by 27
Teo, J. Q.-M., Candra, S. R., Lee, S. J.-Y., Chia, S. Y.-H., Leck, H., Tan, A., Neo, H.-P., Leow, K. W.-L., Cai, Y., Ee, P. L. R., et al. (2017) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-017-0184-1 · Cited by 27
Azoles de antes y ahora: una revisión
Nócua-Báez, L. C., Uribe-Jerez, P., Tarazona-Guaranga, L., Robles, R. L., & Cortés, J. A. (2020) · Revista chilena de infectología · doi:10.4067/s0716-10182020000300219 · Cited by 54
Rizos, E. C., Salanti, G., Kontoyiannis, D. P., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.11.017 · Cited by 28
Pharmacotherapy of yeast infections
Gómez‐López, A., Zaragoza, Ó., Rodríguez-Tudela, J. L., & Cuenca‐Estrella, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.16.2801 · Cited by 36
Soonawala, D., Middelburg, R. A., Egger, M., Vandenbroucke, J. P., & Dekkers, O. M. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyq136 · Cited by 27
Kullberg, B. J., Vasquez, J., Mootsikapun, P., Nucci, M., Paiva, J.-A., Garbino, J., Yan, J. L., Aram, J. A., Capparella, M. R., Conte, U., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx116 · Cited by 27
Antifungal stewardship with an emphasis on candidaemia
Capoor, M. R., Subudhi, C. P. K., Collier, A., & Bal, A. M. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.05.030 · Cited by 30
Brzankalski, G. E., Najvar, L. K., Wiederhold, N. P., Bocanegra, R. A., Fothergill, A. W., Rinaldi, M. G., Pattterson, T. F., & Graybill, J. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn304 · Cited by 29
Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.